Locally Advanced Unresectable Or Metastatic Androgen Receptor Positive Triple Negative Breast Cancer Or Er Low Her2 Negative Breast Cancer Progressive After At Least 1 Prior Cytostatic Regimen In Advanced Setting If Er Low Additionally At Least One Line Of Endocrine Therapy In Advanced Setting clinical trials

Explore recruiting locally advanced unresectable or metastatic androgen receptor positive triple negative breast cancer or er low her2 negative breast cancer progressive after at least 1 prior cytostatic regimen in advanced setting if er low additionally at least one line of endocrine therapy in advanced setting clinical trials.

Also recruiting in Europe

Locally Advanced Unresectable Or Metastatic Androgen Receptor Positive Triple Negative Breast Cancer Or Er Low Her2 Negative Breast Cancer Progressive After At Least 1 Prior Cytostatic Regimen In Advanced Setting If Er Low Additionally At Least One Line Of Endocrine Therapy In Advanced Setting trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A multicenter uncontrolled, open label, prospective non-comparative single arm phase II study with bicalutamide (an antiandrogen) in combination with abemaciclib (an oral CDK 4/6 inhibitor) in 4 cohorts of locoregionally advanced inoperable or metastatic AR positive triple-negative breast cancer (AR+ TNBC).

Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

Locally Advanced Unresectable Or Metastatic Androgen Receptor Positive Triple Negative Breast Cancer Or Er Low Her2 Negative Breast Cancer Progressive After At Least 1 Prior Cytostatic Regimen In Advanced Setting If Er Low Additionally At Least One Line Of Endocrine Therapy In Advanced Setting trials by city

Locally Advanced Unresectable Or Metastatic Androgen Receptor Positive Triple Negative Breast Cancer Or Er Low Her2 Negative Breast Cancer Progressive After At Least 1 Prior Cytostatic Regimen In Advanced Setting If Er Low Additionally At Least One Line Of Endocrine Therapy In Advanced Setting in Toronto Locally Advanced Unresectable Or Metastatic Androgen Receptor Positive Triple Negative Breast Cancer Or Er Low Her2 Negative Breast Cancer Progressive After At Least 1 Prior Cytostatic Regimen In Advanced Setting If Er Low Additionally At Least One Line Of Endocrine Therapy In Advanced Setting in Vancouver Locally Advanced Unresectable Or Metastatic Androgen Receptor Positive Triple Negative Breast Cancer Or Er Low Her2 Negative Breast Cancer Progressive After At Least 1 Prior Cytostatic Regimen In Advanced Setting If Er Low Additionally At Least One Line Of Endocrine Therapy In Advanced Setting in Montreal Locally Advanced Unresectable Or Metastatic Androgen Receptor Positive Triple Negative Breast Cancer Or Er Low Her2 Negative Breast Cancer Progressive After At Least 1 Prior Cytostatic Regimen In Advanced Setting If Er Low Additionally At Least One Line Of Endocrine Therapy In Advanced Setting in Calgary Locally Advanced Unresectable Or Metastatic Androgen Receptor Positive Triple Negative Breast Cancer Or Er Low Her2 Negative Breast Cancer Progressive After At Least 1 Prior Cytostatic Regimen In Advanced Setting If Er Low Additionally At Least One Line Of Endocrine Therapy In Advanced Setting in Edmonton Locally Advanced Unresectable Or Metastatic Androgen Receptor Positive Triple Negative Breast Cancer Or Er Low Her2 Negative Breast Cancer Progressive After At Least 1 Prior Cytostatic Regimen In Advanced Setting If Er Low Additionally At Least One Line Of Endocrine Therapy In Advanced Setting in Ottawa Locally Advanced Unresectable Or Metastatic Androgen Receptor Positive Triple Negative Breast Cancer Or Er Low Her2 Negative Breast Cancer Progressive After At Least 1 Prior Cytostatic Regimen In Advanced Setting If Er Low Additionally At Least One Line Of Endocrine Therapy In Advanced Setting in Winnipeg Locally Advanced Unresectable Or Metastatic Androgen Receptor Positive Triple Negative Breast Cancer Or Er Low Her2 Negative Breast Cancer Progressive After At Least 1 Prior Cytostatic Regimen In Advanced Setting If Er Low Additionally At Least One Line Of Endocrine Therapy In Advanced Setting in Quebec City Locally Advanced Unresectable Or Metastatic Androgen Receptor Positive Triple Negative Breast Cancer Or Er Low Her2 Negative Breast Cancer Progressive After At Least 1 Prior Cytostatic Regimen In Advanced Setting If Er Low Additionally At Least One Line Of Endocrine Therapy In Advanced Setting in Hamilton Locally Advanced Unresectable Or Metastatic Androgen Receptor Positive Triple Negative Breast Cancer Or Er Low Her2 Negative Breast Cancer Progressive After At Least 1 Prior Cytostatic Regimen In Advanced Setting If Er Low Additionally At Least One Line Of Endocrine Therapy In Advanced Setting in Kitchener Locally Advanced Unresectable Or Metastatic Androgen Receptor Positive Triple Negative Breast Cancer Or Er Low Her2 Negative Breast Cancer Progressive After At Least 1 Prior Cytostatic Regimen In Advanced Setting If Er Low Additionally At Least One Line Of Endocrine Therapy In Advanced Setting in London Locally Advanced Unresectable Or Metastatic Androgen Receptor Positive Triple Negative Breast Cancer Or Er Low Her2 Negative Breast Cancer Progressive After At Least 1 Prior Cytostatic Regimen In Advanced Setting If Er Low Additionally At Least One Line Of Endocrine Therapy In Advanced Setting in Halifax Locally Advanced Unresectable Or Metastatic Androgen Receptor Positive Triple Negative Breast Cancer Or Er Low Her2 Negative Breast Cancer Progressive After At Least 1 Prior Cytostatic Regimen In Advanced Setting If Er Low Additionally At Least One Line Of Endocrine Therapy In Advanced Setting in New York Locally Advanced Unresectable Or Metastatic Androgen Receptor Positive Triple Negative Breast Cancer Or Er Low Her2 Negative Breast Cancer Progressive After At Least 1 Prior Cytostatic Regimen In Advanced Setting If Er Low Additionally At Least One Line Of Endocrine Therapy In Advanced Setting in Los Angeles Locally Advanced Unresectable Or Metastatic Androgen Receptor Positive Triple Negative Breast Cancer Or Er Low Her2 Negative Breast Cancer Progressive After At Least 1 Prior Cytostatic Regimen In Advanced Setting If Er Low Additionally At Least One Line Of Endocrine Therapy In Advanced Setting in Chicago Locally Advanced Unresectable Or Metastatic Androgen Receptor Positive Triple Negative Breast Cancer Or Er Low Her2 Negative Breast Cancer Progressive After At Least 1 Prior Cytostatic Regimen In Advanced Setting If Er Low Additionally At Least One Line Of Endocrine Therapy In Advanced Setting in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease